Genetic Technologies Ltd.
GENE
GENE was delisted on the 16th of October, 2024.
11 hedge funds and large institutions have $915K invested in Genetic Technologies Ltd. in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.
38% more funds holding
Funds holding: 8 → 11 (+3)
1% more capital invested
Capital invested by funds: $905K → $915K (+$10K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$169K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$21.7K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
+$1.02K |
| 4 |
PCM
Prelude Capital Management
New York
|
+$611 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$15.4K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$2.08K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$81 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $857K | +$169K | +4,160 | +21% |
|
|
VKH
2
Virtu KCG Holdings
New York
| $24K | -$2.08K | -51 | -7% |
|
|
3
Citadel Advisors
Miami,
Florida
| $19K | +$21.7K | +532 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $5K | -$15.4K | -379 | -74% |
|
|
LTFS
5
Ladenburg Thalmann Financial Services
Miami,
Florida
| $5K | – | – | – |
|
6
Morgan Stanley
New York
| $2K | – | – | – |
|
7
Citigroup
New York
| $1K | – | – | – |
|
|
FANJ
8
Financial Architects (New Jersey)
Marlton,
New Jersey
| $1K | – | – | – |
|
|
PCM
9
Prelude Capital Management
New York
| $1K | +$611 | +15 | New |
|
|
10
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$81 | -2 | -9% |
|
|
CG
11
Cutler Group
San Francisco,
California
| – | +$1.02K | +25 | New |
|
GENE Hedge Fund Activity: Q3 2016 in Review
11 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Genetic Technologies Ltd. (GENE) for Q3 2016, worth a combined $915K — up 1.1% from $905K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new GENE positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $169K. The largest seller was UBS Group, cutting an estimated $15.4K.
- 11 institutional investors held Genetic Technologies Ltd. (GENE) as of Q3 2016, up from 8 in Q2 2016.
- Funds reported $915K of Genetic Technologies Ltd. stock for Q3 2016, up 1.1% quarter-over-quarter.
- 3 funds opened new Genetic Technologies Ltd. positions in Q3 2016 and 0 closed out, a net change of +3 holders.
- The largest Genetic Technologies Ltd. buyer in Q3 2016 was Renaissance Technologies, an estimated $169K added.
- The largest Genetic Technologies Ltd. seller in Q3 2016 was UBS Group, an estimated $15.4K sold.
Based on aggregated 13F filings for Q3 2016.